Hot Stock of the Day: BioLineRx Ltd. (NASDAQ: BLRX)

BioLineRx Ltd. (BLRX) reported recently the completion of patient recruitment in the triple mix arm of its ongoing Phase 2a COMBAT/KEYNOTE -202 study.

” We more than happy to see the triple mix arm of our Phase 2a pancreatic research study advance according to plan,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “This follows extremely appealing preliminary results that existed last month at the ESMO IO conference, demonstrating robust and long lasting responses to the triple mix treatment. As prior to stated, we remain on track to reveal progression-free and general survival information from the triple mix arm in mid-2020.”

An overall of 40 patients identified with unresectable stage IV metastatic pancreatic adenocarcinoma (PDAC), who have advanced following first-line gemcitabine-based therapy, were enrolled as prepared in the triple mix arm focusing on second-line pancreatic cancer patients. Clients receive Motixafortide ( BL-8040) monotherapy priming treatment for 5 days, followed by combination cycles of chemotherapy (Onivyde ®/ 5-fluorouracil/leucovorin), KEYTRUDA ® and Motixafortide until progression. The primary endpoint of the study is the objective action rate (ORR). Secondary endpoints include general survival, development free survival, and illness control rate.

On the other end, the stock has actually been kept in mind 50.97% away from the low rate over the last 52-weeks. The stock altered -0.85% to recent value of $2.34.

The cost continued of -3.65% from the mean of 20 days, -3.88% from mean of 50 days SMA and carried out -34.62% from mean of 200 days cost. Companys performance for the week was -2.50%, 0.00% for month and YTD efficiency remained 4.00%.

.

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Robert Hernandez

Robert Hernandez – Health and Biotech I am Robert Hernandez, I have done my bachelor’s in English literature, and further on I did my master’s in Medicines. My most preferred genre of writing is health and biotech. I have been writing from the past 6 years about articles, web content, and blogs. In my career and education, I like to play along with work. I have also been a teacher in the past for 2 years. I use to teach business and technical writing in a very famous university. However, most recently I am working as an instructor, designer, and training writer. I enjoy socializing a lot. I am a very big extrovert when it comes to nature. A part from all this I enjoy exploring the world and traveling makes me happy.

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Close Bitnami banner
Bitnami